Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 8:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1057–1080 of 2,412 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Laboratory Testing Clear all
Completed No phase listed Observational Accepts healthy volunteers

ALPCO/Calprotectin CLIA Assay: Expected Values of Calprotectin in Healthy Subjects

NCT07089420
View directory record Official record
Conditions
IBD (Inflammatory Bowel Disease), IBS - Irritable Bowel Syndrome, Crohn Disease (CD), UC - Ulcerative Colitis
Interventions
ALPCO Calprotectin CLIA
Device
Lead sponsor
American Laboratory Products Company
Industry
Eligibility
22 Years and older
Enrollment
121 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Salem, New Hampshire
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Oct 21, 2026, 8:22 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Well-Mama Community Doula Navigator Study

NCT05179369
View directory record Official record
Conditions
Pregnancy Related
Interventions
Standard Care with Well-Mama Intervention
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
15 Years to 49 Years · Female only
Enrollment
576 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
2
States / cities
Baton Rouge, Louisiana • Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 21, 2026, 8:22 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Randomized Evaluation of Ten Allergy Skin Prick Test Devices

NCT03509766
View directory record Official record
Conditions
Allergic Rhinitis, Asthma, Food Allergy, Skin Testing
Interventions
Histamine skin testing
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 16, 2018 · Synced Oct 21, 2026, 8:22 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Assessing Continuous Glucose Monitors in Healthy Children

NCT00069602
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Continuous Glucose Monitoring System (CGMS), GlucoWatch G2TM Biographer (GW2B)
Device
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
7 Years to 17 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002
U.S. locations
6
States / cities
Stanford, California • Denver, Colorado • New Haven, Connecticut + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2016 · Synced Oct 21, 2026, 8:22 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Biomarkers of Increased Free Living Sleep Time

NCT04214184
View directory record Official record
Conditions
Sleep Deprivation, Insufficient Sleep Syndrome, Sleep Wake Disorders
Interventions
Increased sleep duration
Behavioral
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 35 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2025
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Oct 21, 2026, 8:22 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Development of a Neurocognitive Screening Test

NCT02597504
View directory record Official record
Conditions
Brain Concussion, Mild Cognitive Impairment
Interventions
Pen and paper neuropsychological test, Quick Test
Other · Device
Lead sponsor
ImPACT Applications, Inc.
Industry
Eligibility
6 Years to 75 Years
Enrollment
1,600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
4
States / cities
Scottsdale, Arizona • Fayetteville, Arkansas • Crofton, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2023 · Synced Oct 21, 2026, 8:22 AM EDT
Completed Not applicable Interventional Results available

Genetically Guided Statin Therapy

NCT01894230
View directory record Official record
Conditions
Hypercholesterolemia, Hydroxy-methylglutaryl-coenzyme A (HMG Co-A) Reductase Inhibitors Adverse Reaction
Interventions
SLCO1B1*5 allele testing, results reported at randomization, SLCO1B1*5 allele testing, results reported at end of study, Genetic testing for SLCO1B1*5 allele
Genetic
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
2
States / cities
Travis Air Force Base, California • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 23, 2017 · Synced Oct 21, 2026, 8:22 AM EDT
Recruiting Not applicable Interventional

WATCH (Wearable Artificial inTelligence for Cardiac Function and Health Monitoring)

NCT07058064
View directory record Official record
Conditions
Lymphoma, Sarcoma
Interventions
Electrocardiogram, Echocardiogram, LVEF echocardiogram, Apple Watch, Biospecimen collection, Questionnaires, Cardio-pulmonary exercise test, 6 minute walk test, Grip strength test
Procedure · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Oct 21, 2026, 8:22 AM EDT
Completed Phase 2 Interventional Results available

Bone Marrow Transplantation vs Standard of Care in Patients With Severe Sickle Cell Disease (BMT CTN 1503)

NCT02766465
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Busulfan, Fludarabine, r-ATG, Hematopoietic Cell Transplant, Tacrolimus, Methotrexate, Standard of Care, Alemtuzumab, Total Body Irradiation (TBI), Sirolimus, Melphalan, G-CSF
Drug · Procedure
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
15 Years to 40 Years
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
35
States / cities
Oakland, California • Washington D.C., District of Columbia • Gainesville, Florida + 25 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2025 · Synced Oct 21, 2026, 8:22 AM EDT
Completed Not applicable Interventional Results available

Performance of a New Glucose Meter System

NCT01264016
View directory record Official record
Conditions
Diabetes
Interventions
Investigational Blood Glucose Monitoring System
Device
Lead sponsor
Ascensia Diabetes Care
Industry
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Escondido, California
Source: ClinicalTrials.gov public record
Updated Feb 29, 2016 · Synced Oct 21, 2026, 8:22 AM EDT
Recruiting No phase listed Observational

Role of Phosphatidylethanol in Predicting Perioperative Outcomes of Admitted Patients at UHCMC

NCT06864819
View directory record Official record
Conditions
Postoperative Complications, Alcohol Use Disorder
Interventions
Blood Draw
Other
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
21 Years to 79 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 21, 2026, 8:22 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

The PRIME-CRC Trial to Promote CRC Screening in Rural Communities

NCT04313114
View directory record Official record
Conditions
Colorectal Cancer
Interventions
health literacy appropriate education and demonstration, shared decision making, automated call reminders or automated texts
Behavioral
Lead sponsor
Louisiana State University Health Sciences Center Shreveport
Other
Eligibility
45 Years to 75 Years
Enrollment
804 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
3
States / cities
Bastrop, Louisiana • Marion, Louisiana • Saint Joseph, Louisiana
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 21, 2026, 8:22 AM EDT
Active, not recruiting Phase 2 Interventional

Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue Sarcoma

NCT05836571
View directory record Official record
Conditions
Locally Advanced Extraskeletal Myxoid Chondrosarcoma, Locally Advanced Leiomyosarcoma, Locally Advanced Liposarcoma, Locally Advanced Undifferentiated Pleomorphic Sarcoma, Locally Advanced Unresectable Soft Tissue Sarcoma, Metastatic Soft Tissue Sarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma, Unresectable Leiomyosarcoma, Unresectable Liposarcoma, Unresectable Undifferentiated Pleomorphic Sarcoma
Interventions
Biopsy Procedure, Biospecimen Collection, Cabozantinib, Computed Tomography, Ipilimumab, Magnetic Resonance Imaging, Nivolumab
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute LAO
Other
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
26
States / cities
Duarte, California • Irvine, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 21, 2026, 8:22 AM EDT
Active, not recruiting Phase 3 Interventional

Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial)

NCT02595944
View directory record Official record
Conditions
Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7
Interventions
Biospecimen Collection, Computed Tomography, Echocardiography Test, Nivolumab, Observation Activity, Positron Emission Tomography
Procedure · Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
903 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
884
States / cities
Birmingham, Alabama • Daphne, Alabama • Mobile, Alabama + 638 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 21, 2026, 8:22 AM EDT
Completed Not applicable Interventional

Cognitive-Motivational Behavior Therapy for Pathological Gamblers

NCT01135264
View directory record Official record
Conditions
Pathological Gambling
Interventions
CBT, CMBT
Behavioral
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 24, 2017 · Synced Oct 21, 2026, 8:22 AM EDT
Not listed No phase listed Observational

Finding the Cause for Post-Transplant Diabetes Mellitus After Allogeneic Hematopoietic Cell Transplant

NCT03415139
View directory record Official record
Conditions
Diabetes Mellitus, Cancer
Interventions
Oral Glucose Tolerance Test (OGTT), 2 OGTTs with and without GLP-1 analogue, Hyperglycemic clamp procedure
Drug
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years to 90 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 28, 2022 · Synced Oct 21, 2026, 8:22 AM EDT
Completed No phase listed Observational

Study of Kidney Tumors in Younger Patients

NCT00898365
View directory record Official record
Conditions
Adult Cystic Nephroma, Anaplastic Kidney Wilms Tumor, Angiolipoma, Cellular Congenital Mesoblastic Nephroma, Classic Congenital Mesoblastic Nephroma, Clear Cell Sarcoma of the Kidney, Congenital Mesoblastic Nephroma, Cystic Partially Differentiated Kidney Nephroblastoma, Diffuse Hyperplastic Perilobar Nephroblastomatosis, Extrarenal Rhabdoid Tumor, Kidney Medullary Carcinoma, Kidney Neoplasm, Kidney Oncocytoma, Kidney Wilms Tumor, Metanephric Adenofibroma, Metanephric Adenoma, Metanephric Stromal Tumor, Metanephric Tumor, Mixed Congenital Mesoblastic Nephroma, Ossifying Renal Tumor of Infancy, Papillary Renal Cell Carcinoma, Renal Cell Carcinoma, Renal Cell Carcinoma Associated With Xp11.2 Translocations/TFE3 Gene Fusions, Rhabdoid Tumor of the Kidney, Wilms Tumor
Interventions
Cytology Specimen Collection Procedure, Laboratory Biomarker Analysis
Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 29 Years
Enrollment
8,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2026
U.S. locations
214
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 153 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 21, 2026, 8:22 AM EDT
Not yet recruiting No phase listed Observational

SNAPS Breast Cancer Patient Study Breast Cancer Patients

NCT05370300
View directory record Official record
Conditions
Breast Cancer, Breast Cancer Female
Interventions
Blood test
Diagnostic Test
Lead sponsor
Immunis.AI
Industry
Eligibility
18 Years and older · Female only
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 6, 2024 · Synced Oct 21, 2026, 8:22 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Short Term Effects of Oceanix Supplementation on Recovery

NCT04315077
View directory record Official record
Conditions
Oxidative Stress, Muscle Strength, Resistance Training, Muscle Damage, Immune Suppression
Interventions
Oceanix®, Resistance Training
Dietary Supplement · Other
Lead sponsor
Applied Science & Performance Institute
Industry
Eligibility
18 Years to 45 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Nov 19, 2020 · Synced Oct 21, 2026, 8:22 AM EDT
Completed Not applicable Interventional

A Communication Tool to Assist Older Adults Facing Dialysis Choices

NCT04466865
View directory record Official record
Conditions
Palliative Care, Kidney Failure, Chronic, Decision Making, Decision Support Techniques, Renal Dialysis, Dialysis, Kidney Diseases, Nephrologists, Decision Aid, End of Life, End-Stage Renal Disease, Late-Stage Renal Disease, Communication, Life-Supporting Treatments
Interventions
Best Case/Worst Case communication tool training
Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
60 Years and older
Enrollment
407 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
11
States / cities
Denver, Colorado • Chicago, Illinois • Baltimore, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Oct 21, 2026, 8:22 AM EDT
Recruiting Phase 2 Interventional

Effects of Relugolix vs Leuprolide on Cardiac Function in Patients With Prostate Cancer

NCT06330805
View directory record Official record
Conditions
Prostate Adenocarcinoma, Stage IIB Prostate Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8
Interventions
Biospecimen Collection, Contrast Agent, Leuprolide, Magnetic Resonance Imaging, Physical Performance Testing, Relugolix
Procedure · Other · Drug
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Oct 21, 2026, 8:22 AM EDT
Completed Phase 3 Interventional Results available

Bioequivalence Study With Clinical Endpoint Comparing Brinzolamide 1% Ophthalmic Suspension to Azopt® 1% Ophthalmic Suspension In the Treatment of Chronic Open Angle Glaucoma or Ocular Hypertension in Both Eyes

NCT02512042
View directory record Official record
Conditions
Glaucoma
Interventions
Test-Brinzolamide 1% Ophthalmic suspension, Reference-Brinzolamide 1% Ophthalmic suspension
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years and older
Enrollment
973 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
10
States / cities
Newport Beach, California • Largo, Florida • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2020 · Synced Oct 21, 2026, 8:22 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Advancing Prevention of Pulmonary Fibrosis

NCT04564183
View directory record Official record
Conditions
IPF, Pulmonary Fibrosis, ILD
Interventions
Sample collection, Questionnaires, High resolution CT scan of the chest, Pulmonary Function Test
Other · Radiation · Diagnostic Test
Lead sponsor
University of Colorado, Denver
Other
Eligibility
40 Years to 75 Years
Enrollment
800 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 25, 2025 · Synced Oct 21, 2026, 8:22 AM EDT
Active, not recruiting Phase 1 Interventional

Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advanced Unresectable Pancreatic Cancer

NCT05411094
View directory record Official record
Conditions
Locally Advanced Pancreatic Carcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Unresectable Pancreatic Carcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Durvalumab, Magnetic Resonance Imaging, Olaparib
Procedure · Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
10
States / cities
Irvine, California • Los Angeles, California • Orange, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 21, 2026, 8:22 AM EDT